Cantor Fitzgerald Reaffirms Neutral Rating for Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals (NASDAQ:SUPN)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued on Wednesday,Benzinga reports. They currently have a $36.00 price objective on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 13.35% from the stock’s previous close.

Supernus Pharmaceuticals Stock Performance

SUPN opened at $31.76 on Wednesday. The business’s fifty day moving average is $37.19 and its two-hundred day moving average is $35.34. The company has a market cap of $1.75 billion, a price-to-earnings ratio of 29.68 and a beta of 0.90. Supernus Pharmaceuticals has a one year low of $25.53 and a one year high of $40.28.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is owned by corporate insiders.

Institutional Trading of Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vident Advisory LLC lifted its position in shares of Supernus Pharmaceuticals by 2.2% in the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company’s stock valued at $520,000 after acquiring an additional 309 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after acquiring an additional 352 shares in the last quarter. Summit Investment Advisors Inc. lifted its position in shares of Supernus Pharmaceuticals by 7.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company’s stock valued at $190,000 after acquiring an additional 369 shares in the last quarter. Bank of Montreal Can lifted its position in shares of Supernus Pharmaceuticals by 6.6% in the fourth quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock valued at $275,000 after acquiring an additional 473 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its position in shares of Supernus Pharmaceuticals by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock valued at $800,000 after acquiring an additional 560 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.